Skip to main content
All lobbying filings

LMH STRATEGIC SOLUTIONS

Lobbying for ALKERMES, INC. · Biopharmaceutical company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 17, 2026

Official filing document

 Bills named in this filing 1
 Lobbying activity 1
Medicare/Medicaid

Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem